Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.
NYS Entity Status
NYS Filing Date
NOVEMBER 09, 1999
NYS DOS ID#
CT CORPORATION SYSTEM
111 EIGHTH AVE.
NEW YORK, NEW YORK, 10011
NYS Entity Type
FOREIGN LIMITED LIABILITY COMPANY
2003 - QUAD VENTURES LLC
1999 - QUAD CAPITAL PARTNERS LLC
Around the Web
- The Top 10 Moments of New York Fashion Week
By THE NEW YORK TIMES - Friday Sep 15, 2017
- Women of Sex Tech, Unite
By ANNA NORTH - Friday Aug 18, 2017
New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.
- Race to offer consumers a ‘quad play’ making M&A mayhem
By Richard Morgan - Tuesday Jun 27, 2017
The race to offer consumers a “quad play” — phone, TV, broadband and wireless — is making for M&A mayhem. Comcast and Charter Communications, the country’s two largest cable operators, have reset the deal agenda for cable and telecom companies by entering into exclusive negotiations with Sprint. Talks between the cable behemoths and Sprint, the...
- HP unveils new quad-core Spectre 13 and Spectre x360 laptops
By Dean Takahashi - Wednesday Oct 4, 2017
HP introduced the flagship laptops of its fall PC lineup today, unveiling the quad-core HP Spectre 13 and HP Spectre x360 consumer laptops. The HP Spectre 13 is a 13-inch laptop with a 4K screen, and the Spectre x360 is a 2-in-1 hybrid that can convert from a laptop to a tablet. The sleek and light laptops […]
- Fit City: Taking Night-Life Cue, Gyms Lower the Lights
By TATIANA BONCOMPAGNI - Tuesday Jun 13, 2017
Cycling, boxing and running studios, as well as some full-service gyms, are using sophisticated lighting systems to heighten the exercise experience.
- IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
By Ben Fidler - Thursday Aug 3, 2017
Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]